Table 5. Association between FTO genotype and prostate cancer outcomes adjusted by age and study centre.

	TA vs TT		AA vs TT		per allele effect
	Odds Ratio (95%CI)	p	Odds Ratio (95%CI)	p	Odds Ratio (95%CI)	p
Cancer cases (n = 1550) vs matched controls (n = 1815)	0.96 (0.83–1.12)	0.62	0.86 (0.70–1.06)	0.16	0.94 (0.85–1.03)	0.18
Cancer cases (n = 1550) vs low PSA controls (n = 1175)	0.99 (0.83–1.17)	0.87	0.82 (0.65–1.03)	0.09	0.92 (0.82–1.03)	0.14
Cancer cases (n = 1550) vs all controls (n = 2990)	0.98 (0.85–1.12)	0.73	0.84 (0.70–1.02)	0.08	0.93 (0.85–1.02)	0.12
Low grade cancers (n = 1096) vs all controls (n = 2990)	0.94 (0.80–1.09)	0.38	0.78 (0.63–0.97)	0.02	0.90 (0.81–0.99)	0.03
Localized stage (n = 1350) vs all controls (n = 2990)	0.95 (0.83–1.10)	0.50	0.87 (0.71–1.05)	0.15	0.94 (0.85–1.03)	0.16
High grade (n = 449) vs low grade (n = 1096)	1.20 (0.94–1.54)	0.14	1.33 (0.95–1.88)	0.10	1.16 (0.99–1.37)	0.07
Advanced stage (n = 196) vs localized stage (n = 1350)	1.27 (0.91–1.77)	0.16	0.79 (0.47–1.34)	0.38	0.99 (0.79–1.23)	0.90
High grade (n = 449) vs all controls (n = 2990)	1.09 (0.87–1.36)	0.45	1.01 (0.75–1.37)	0.94	1.02 (0.89–1.18)	0.78
Advanced stage (n = 196) vs all controls (n = 2990)	1.14 (0.83–1.57)	0.40	0.68 (0.41–1.12)	0.13	0.91 (0.73–1.12)	0.36